Related Experiment Videos
Ongoing trials: what should we expect after ALLHAT?
Ji-Guang Wang1, Jan A Staessen, Anthony M Heagerty
1Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK. tony.heagerty@man.ac.uk
Insights
Lowering blood pressure is key in hypertension management, with all drugs showing similar effectiveness. Future research will explore drug combinations and novel agents to reduce cardiovascular and cognitive risks.
Area of Science:
- Cardiovascular Medicine
- Hypertension Research
- Pharmacology
Background:
- The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT) results are a landmark in hypertension research.
- Recent meta-analyses support the ALLHAT findings, emphasizing blood pressure reduction.
Purpose of the Study:
- To synthesize findings from ALLHAT and meta-analyses to inform hypertension management strategies.
- To evaluate the role of blood pressure targets, drug safety, aspirin, and statins in a holistic, risk-based approach.
- To identify future research directions for optimizing hypertension treatment and preventing cognitive decline.
Main Methods:
- Analysis of the ALLHAT trial results.
- Integration with new meta-analysis data on antihypertensive agents.
- Consideration of evidence on blood pressure targets, drug safety, aspirin, and statins.
Main Results:
- Lowering blood pressure is the paramount goal in hypertension management.
- Current evidence indicates similar efficacy across different antihypertensive drug classes.
- Limited evidence supports pressure-independent benefits for any specific drug class.
Conclusions:
- Hypertension management should be holistic and risk-based, integrating blood pressure control with other cardiovascular risk factors.
- Future research should focus on combination therapies and novel agents targeting arterial stiffness and cognitive impairment.
- Evidence supports a unified approach to managing hypertension and its associated risks, including cardiovascular events and dementia.
Abstract:
The publication of the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT) results, when used in conjunction with a new meta-analysis, provides hypertension research with a watershed. Data demonstrate clearly that lowering blood pressure is the most important aspect of hypertension management, and that all agents are similarly effective. There is little sustainable evidence for pressure-independent advantages for any class of drug at this time. Therefore, by combining these findings with additional information on target levels of blood pressure and safety, plus the use of aspirin and statins, we can formulate health care policies that attack hypertension in a holistic risk-based way. The future will focus on gaining extra benefit for patients by testing the efficacy and superiority of drug combinations using novel agents that favorably influence intermediate markers such as arterial stiffness, and arresting the ever-increasing burden of cognitive impairment and dementia.